{"id":"nct:NCT07894887","kind":"trial","title":"EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)","authors":["Editas Medicine, Inc."],"author_count":1,"year":2026,"published":"2026-10-26","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT07894887","source_url":"https://clinicaltrials.gov/study/NCT07894887","archive_url":"https://space-kitty.com/papers/nct:NCT07894887","updated":"2026-10-26","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"A phase 1/2, two-part trial consisting of an open label dose-escalation part and a randomized, double blind, placebo-controlled part to investigate safety, tolerability, pharmacokinetics, and efficacy with EDIT-401 gene editing in adult male and female participants 18 to 65 years of age who require additional lowering of low-density lipoprotein cholesterol (LDL-C) such as those with clinical diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH).","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Heterozygous Familial Hypercholesterolemia (HeFH)"],"details":{"acronym":null,"status":"NOT_YET_RECRUITING","phase":"PHASE1, PHASE2","study_type":"INTERVENTIONAL","enrollment":56,"sponsor":"Editas Medicine, Inc.","conditions":["Heterozygous Familial Hypercholesterolemia (HeFH)"],"interventions":["DRUG: Drug: EDIT-401","OTHER: Placebo"],"start_date":"2026-11-01","start_date_type":"ESTIMATED","primary_completion_date":"2029-06-01","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-editing-therapies","name":"CRISPR & Gene-Editing Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"gene-editing-therapies","title":"CRISPR & Gene-Editing Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/gene-editing-therapies"}]}